Evidence map›Paper›PMID 34225797›Full record

ArticleAlzheimer's research & therapy2021

Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease.

Zhenxu Xiao, Xue Wu, Wanqing Wu, Jingwei Yi, Xiaoniu Liang, Saineng Ding, Li Zheng, Jianfeng Luo, Hongchen Gu, Qianhua Zhao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. AD-related plasma biomarkers in centenarians: links to cognition and neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Zhenxu Xiao *Institute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China.
Xue Wu *School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Wanqing WuInstitute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China.
Jingwei YiSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Xiaoniu LiangInstitute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China.
Saineng DingInstitute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China.
Li ZhengInstitute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China.
Jianfeng LuoDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Hongchen GuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Qianhua ZhaoInstitute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China. qianhuazhao@fudan.edu.cn.
Hong XuSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China. xuhong@sjtu.edu.cn.
Ding DingInstitute of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd, Shanghai, China.
Fudan University · CNShanghai Jiao Tong University · CNHuashan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer's disease (AD). However, profiles of the biomarkers and the associations with cognition across a spectrum of cognitive stages have seldom been reported.

methodsWe recruited 320 individuals with cognitive impairment and 131 cognitively normal participants from a memory clinic and a community cohort. Participants were classified into 6 groups based on their Clinical Dementia Rating (CDR) scores and clinical diagnosis, including AD, amnestic mild cognitive impairment (aMCI), and normal cognition (NC). A battery of neuropsychological tests was used to assess the global and domain-specific cognition. Plasma Aβ

resultsAll the plasma markers (Aβ

conclusionsPlasma p-tau181 had correlations with broader cognitive domains, suggesting its potential as a promising clinical-relevant blood-based biomarker.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersCognitionHumansNeuropsychological Teststau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseaseCDRCognitive domainPlasma p-tau181Simoa

Identifiers

PMID34225797
PMCPMC8259165
OpenAlexW3179841967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.